FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to treatment of relapsing-remitting multiple sclerosis. For this purpose modulator of receptor S1P is introduced to patient, requiring such treatment, in day dose 0.5 mg. Modulator of receptor S1P represents 2-amino-2-[2-(4-octylphenyl)ethyl]propan-1,3-diol or its pharmaceutically acceptable salt, for instance hydrochloride.
EFFECT: invention makes it possible to slow down progression of relapsing-remitting multiple sclerosis.
3 cl
Title | Year | Author | Number |
---|---|---|---|
S1P RECEPTOR MODULATORS FOR MULTIPLE SCLEROSIS TREATMENT | 2007 |
|
RU2617502C2 |
SIP RECEPTOR MODULATORS FOR TREATING MULTIPLE SCLEROSIS | 2007 |
|
RU2495664C2 |
LIQUID COMPOSITIONS | 2006 |
|
RU2428180C2 |
LIQUID FORMULATIONS | 2006 |
|
RU2470631C2 |
COMBINATIONS WHICH INCLUDE RECEPTOR S1P AGONIST AND JAK3 KINASE INHIBITOR | 2005 |
|
RU2415678C2 |
USING SIP RECEPTOR MODULATORS IN OPHTHALMOLOGY | 2006 |
|
RU2497513C2 |
ORGANIC COMPOUNDS | 2004 |
|
RU2358716C2 |
ORAL PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475237C2 |
METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475236C2 |
COMPOSITIONS CONTAINING MODULATORS OF SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR | 2008 |
|
RU2779056C2 |
Authors
Dates
2015-11-27—Published
2007-06-25—Filed